Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1901.35% | ||
| Return on Equity | n/a | ||
| Operating Margin | -35.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 54.57 | 69.83 | 93.63 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DNA X, Inc., formerly Sonim Technologies, Inc., is a digital asset management platform, building on the digital asset trading platform. The Company operates an artificial intelligence (AI) and crypto trading platform designed to automate trading strategies using machine learning technologies. It provides a digital asset trading platform that allows users to trade or swap cryptocurrencies for other cryptocurrencies or cash equivalent currencies. The Company’s DNA X trading website enables users to implement strategies to take advantage of fluctuations in relative values of cryptocurrency pairs. The platform allows users to set up automated trading strategies, monitor other traders’ trading strategies in real time, and simulate trades. The Company generates revenue from trading commissions based on the value of trades executed on its platform. It serves individual investors from around the world and supports its operations through subsidiaries located in China, Germany, and Hong Kong.
Directors
- John Kneuer NEC (52)
- Robert Tirva PRE (54)
- Bengt Jonassen VPR
- Alan Howe IND (60)
- Michael Mulica IND (58)
- Susan Swenson IND (73)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- August 5th, 1999
- Public Since
- May 10th, 2019
- No. of Shareholders
- 30
- No. of Employees
- 4
- Sector
- Computers, Phones & Household Electronics
- Industry
- Technology
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,488,268
- Address
- 4445 Eastgate Mall, Suite 200, SAN DIEGO, 92121
- Web
- https://www.sonimtech.com
- Phone
- +1 6503788100
- Contact
- Clay Crolius
- Auditors
- BAKER TILLY US LLP
Latest News for SONM
Upcoming Events for SONM
DNA X Inc Annual Shareholders Meeting
Q2 2026 DNA X Inc Earnings Release
Q3 2026 DNA X Inc Earnings Release
Similar to SONM
BeLive Holdings
NASDAQ Capital Market
Data I/O
NASDAQ Capital Market
Galleinphi
NASDAQ Capital Market
Hitek Global
NASDAQ Capital Market
Jingrui Wang Pu Holdings
NASDAQ Capital Market
FAQ
As of Today at 11:18 UTC, shares in DNA X are trading at $5.70. This share price information is delayed by 15 minutes.
Shares in DNA X last closed at $5.70 and the price had moved by -82.01% over the past 365 days. In terms of relative price strength the DNA X share price has underperformed the S&P500 Index by -84.9% over the past year.
The overall consensus recommendation for DNA X is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDNA X does not currently pay a dividend.
DNA X does not currently pay a dividend.
DNA X does not currently pay a dividend.
To buy shares in DNA X you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.70, shares in DNA X had a market capitalisation of $8.48m.
Here are the trading details for DNA X:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SONM
Based on an overall assessment of its quality, value and momentum DNA X is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DNA X is $8.00. That is 40.35% above the last closing price of $5.70.
Analysts covering DNA X currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DNA X. Over the past six months, its share price has outperformed the S&P500 Index by +62.2%.
As of the last closing price of $5.70, shares in DNA X were trading -12.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DNA X PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DNA X's management team is headed by:
- John Kneuer - NEC
- Robert Tirva - PRE
- Bengt Jonassen - VPR
- Alan Howe - IND
- Michael Mulica - IND
- Susan Swenson - IND